wuhan
rapidli
spread
throughout
world
critic
ill
patient
high
mortal
rate
aim
assess
effect
continu
renal
replac
therapi
crrt
allcaus
mortal
patient
undergo
invas
mechan
ventil
east
respiratori
syndrom
coronaviru
merscov
march
th
infect
peopl
worldwid
caus
death
data
still
increas
wuhan
fatal
rate
note
critic
ill
patient
high
mortal
rate
studi
critic
ill
patient
wuhan
patient
die
day
mortal
rate
patient
requir
mechan
ventil
accumul
evid
strongli
demonstr
system
inflammatori
respons
acut
kidney
injuri
aki
fluid
overload
fo
associ
high
mortal
sever
sepsi
critic
ill
patient
overwhelm
inflamm
includ
creactiv
protein
crp
interleukin
il
tumor
necrosi
factor
observ
consist
patient
suffer
sarscov
merscov
continu
renal
replac
therapi
crrt
great
help
critic
ill
patient
control
electrolyt
acidbas
derang
also
remov
inflammatori
mediat
improv
oxygen
fluid
overload
crrt
appli
critic
ill
patient
includ
patient
sarscov
merscov
viral
infecti
diseas
ebola
viru
diseas
howev
benefit
crrt
still
consist
conclus
critic
ill
patient
crrt
significantli
reduc
level
decreas
hospit
mortal
rate
pediatr
sever
sepsi
especi
patient
acut
respiratori
distress
syndrom
ard
besid
metaanalysi
reveal
patient
receiv
crrt
significantli
lower
mortal
compar
convent
therapi
hover
crrt
associ
increas
mortal
patient
merscov
relationship
crrt
patient
outcom
vari
patient
differ
diseas
effect
modal
anticoagul
vascular
access
manag
time
initi
intens
crrt
date
specif
treatment
confirm
effect
support
treatment
remain
essenti
far
know
effect
crrt
critic
ill
patient
report
retrospect
cohort
studi
aim
explor
effect
crrt
allcaus
mortal
patient
undergo
invas
mechan
ventil
risk
factor
mortal
patient
crrt
treatment
laboratori
data
collect
throughout
studi
follow
routin
blood
test
blood
glucos
total
cholesterol
hypersensit
creactiv
protein
hcrp
procalcitonin
ferritin
coagul
function
liver
renal
function
lactic
acid
high
sensit
cardiac
troponin
hsctni
ntermin
probrain
natriuret
peptid
ntprobnp
inflammatori
factor
includ
receptor
inform
obtain
manag
establish
data
collect
form
two
research
independ
review
collect
data
perform
crrt
ultrafiltr
rate
mlkghr
perform
use
commerci
avail
pumpdriven
machin
prismaflex
gambro
sweden
multifiltr
freseniu
germani
filter
gambro
oxiri
baxter
freseniu
patient
aki
hemofiltr
plu
hemodialysi
perform
blood
flow
rate
set
mlkgmin
clearanc
rate
set
mlmin
filter
circuit
prewash
salin
contain
iul
heparin
vascular
access
obtain
central
venou
cathet
covidien
usa
femor
vein
follow
patient
electron
hospit
medic
record
outcom
death
patient
follow
death
march
th
survivor
follow
least
one
week
loss
followup
patient
numer
data
present
mean
standard
deviat
sd
median
interquartil
rang
iqr
analyz
use
student
ttest
mannwhitney
u
test
depend
data
distribut
categor
variabl
display
frequenc
percentag
analyz
use
chisquar
test
kaplanmei
method
use
estim
surviv
logrank
test
use
evalu
differ
two
group
cox
regress
model
conduct
adjust
potenti
confound
includ
age
sex
baselin
valu
averag
valu
test
start
invas
mechan
ventil
endpoint
univari
cox
proport
hazard
regress
analys
perform
allcaus
mortal
signific
variant
univari
analysi
variabl
clinic
signific
select
inclus
multivari
backward
stepwis
cox
regress
analysi
spss
ibm
corpor
armonk
ny
statist
softwar
use
statist
analysi
graphpad
prism
graphpad
softwar
usa
use
statist
analysi
visual
pvalu
less
consid
signific
research
funder
involv
studi
design
data
collect
data
analysi
data
interpret
report
write
correspond
author
full
access
data
studi
final
respons
decis
submit
public
total
patient
invas
mechan
ventil
enrol
studi
tabl
show
baselin
characterist
cohort
patient
men
women
rang
age
year
common
comorbid
factor
patient
invas
mechan
ventil
hypertens
cardiac
diseas
meanmedian
level
inflammatori
marker
includ
white
blood
cell
count
neutrophil
count
hcrp
procalcitonin
ferritin
cardiac
injuri
biomark
includ
hsctni
ntprobnp
higher
normal
divid
studi
particip
two
group
accord
crrt
treatment
twentytwo
patient
receiv
crrt
crrt
group
fourteen
patient
noncrrt
group
differ
two
group
baselin
age
sex
comorbid
complic
treatment
laboratori
find
except
patient
receiv
crrt
higher
level
aspart
aminotransferas
serum
creatinin
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
mean
followup
period
day
followup
patient
crrt
group
patient
noncrrt
group
die
kaplanmei
analysi
indic
patient
crrt
group
fare
prolong
surviv
noncrrt
group
figur
cox
regress
analysi
seven
differ
model
use
analyz
adjust
hazard
ratio
crrt
treatment
consist
associ
crrt
treatment
reduc
risk
mortal
remain
signific
adjust
select
confound
factor
age
sex
baselin
laboratori
find
averag
valu
test
start
invas
mechan
ventil
endpoint
adjust
hazard
ratio
ahr
crrt
treatment
fluctuat
tabl
conduct
univari
multivari
cox
proport
hazard
regress
analysi
allcaus
mortal
patient
undergo
invas
mechan
ventil
crrt
adjust
prognost
signific
clinic
factor
includ
age
sex
inflammatori
factor
coagul
function
liver
renal
function
cardiac
function
demonstr
older
age
higher
level
receptor
hsctni
ntprobnp
significantli
associ
increas
risk
allcaus
mortal
tabl
knowledg
current
studi
first
cohort
studi
estim
associ
crrt
treatment
mortal
patient
invas
mechan
ventil
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
ahr
rang
seven
differ
model
excess
inflamm
character
uncontrol
releas
proinflammatori
cytokin
circul
main
caus
death
sepsi
infect
influenza
viru
ebola
viru
merscov
sarscov
studi
found
inflammatori
storm
might
play
crucial
role
critic
patient
meanmedian
level
inflammatori
marker
receptor
white
blood
cell
count
neutrophil
count
hcrp
procalcitonin
ferritin
higher
normal
exampl
averag
peak
pgml
time
higher
upper
limit
normal
valu
refer
rang
pgml
inflammatori
storm
may
origin
follow
aspect
first
infect
patient
bind
human
wide
express
multipl
organ
throughout
bodi
might
lead
multisystem
inflamm
aceang
pathway
ma
receptor
pathway
second
report
antibodi
depend
enhanc
ade
due
prior
exposur
coronavirus
might
also
involv
ade
elicit
sustain
inflamm
lymphopenia
andor
cytokin
storm
make
possibl
explan
geograph
limit
sever
case
third
combin
infect
may
lead
sever
system
inflammatori
respons
inde
studi
patient
combin
infect
organ
eg
urinari
tract
blood
pathogen
eg
influenza
viru
fungu
fourth
shock
hypoxemia
coagul
pathway
abnorm
critic
patient
could
aggrav
system
inflammatori
respons
becom
viciou
cycl
threaten
life
studi
crrt
associ
prolong
surviv
patient
invas
mechan
ventil
crrt
wide
use
blood
purif
therapi
achiev
high
solut
clearanc
rate
diffus
convect
ultrafiltr
adsorpt
primari
goal
crrt
compens
loss
renal
function
associ
sequela
includ
urem
toxin
electrolyt
disturb
metabol
acidosi
volum
overload
besid
crrt
also
remov
cytokin
bloodstream
emerg
evid
shown
crrt
associ
significantli
lower
mortal
patient
sever
sepsi
addit
patient
acut
respiratori
distress
syndrom
crrt
could
remov
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
inflammatori
mediat
modul
immun
function
unregul
oxygen
thu
improv
patient
prognosi
howev
controversi
whether
crrt
benefici
viral
pneumonia
crrt
report
posit
effect
treatment
adenoviru
pneumonia
studi
reveal
crrt
risk
factor
mortal
patient
merscov
although
crrt
treatment
improv
patient
surviv
patient
crrt
treatment
die
followup
patient
crrt
explor
risk
factor
death
better
manag
treatment
deriv
older
age
higher
level
receptor
hsctni
ntprobnp
independ
associ
higher
allcaus
mortal
patient
crrt
known
lymphocytestimul
factor
produc
activ
monocytemacrophag
play
immunomodulatori
role
induc
synthesi
acut
phase
protein
caus
fever
cachexia
activ
antigenpres
cell
cell
promot
prolifer
secret
antibodi
b
cell
innat
acquir
immun
receptor
wide
express
surfac
target
cell
includ
cell
b
cell
monocyt
macrophag
promot
cytotox
action
secret
antibodi
product
nonspecif
cytotoxin
elev
level
receptor
associ
higher
risk
allcaus
mortal
patient
crrt
indic
overact
inflamm
immun
respons
might
still
risk
factor
death
inflammatori
mediat
biomark
need
time
monitor
effect
intervent
need
explor
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
studi
ctni
ntprobnp
associ
increas
risk
mortal
patient
crrt
ctni
constitut
cardiac
troponin
togeth
troponin
c
degrad
cardiac
muscl
fiber
event
myocardi
cell
injuri
elev
ctni
serumreflect
damag
cardiomyocyt
high
myocardi
specif
patient
increas
ctni
level
show
higher
inicu
mortal
pneumonia
ntprobnp
natur
hormon
biolog
activ
synthes
cardiomyocyt
mainli
express
ventricl
rapid
synthesi
releas
ntprobnp
blood
due
myocardi
dilat
regul
cardiac
function
among
patient
left
ventricular
dysfunct
ntprobnp
cutoff
pgml
optim
predict
shortterm
mortal
patient
sepsi
therefor
patient
elev
ctni
ntprobnp
given
enough
attent
activ
treatment
limit
experi
first
retrospect
design
warrant
prospect
doubleblind
random
control
studi
second
sampl
size
studi
larg
enough
third
singlecent
studi
multicent
studi
need
confirm
summari
demonstr
crrt
could
improv
patient
surviv
might
independ
protect
factor
patient
surviv
might
independ
protect
factor
patient
invas
mechan
ventil
patient
undergo
crrt
older
age
higher
level
receptor
hsctni
ntprobnp
independ
associ
higher
allcaus
mortal
prospect
multicent
studi
larger
sampl
size
requir
author
declar
compet
interest
permiss
correspond
author
provid
particip
data
without
name
identifi
studi
protocol
statist
analysi
plan
inform
consent
form
data
provid
articl
publish
data
made
public
research
team
provid
email
address
commun
correspond
author
right
decid
whether
share
data
base
research
object
plan
provid
tabl
comparison
baselin
demograph
clinic
characterist
patient
undergo
invas
mechan
ventil
patient
without
crrt
treatment
cohort
patient
crrt
group
noncrrt
group
p
